Monte Rosa Therapeutics (GLUE) Net Cash Flow (2020 - 2026)

Monte Rosa Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at $30.0 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 120.57% year-over-year to $30.0 million; the TTM figure through Mar 2026 stood at $81.4 million (up 483.85% YoY), while the FY2025 annual figure was -$94.3 million, down 197.76% from the prior year.
• Net Cash Flow was $30.0 million for Q1 2026 at Monte Rosa Therapeutics, up from -$78.5 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $138.9 million in Q3 2025 to a low of -$207.8 million in Q1 2022.
• Historically, Net Cash Flow has averaged -$11.0 million across 5 years, with a median of -$3.1 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow tumbled 816.59% in 2024, then soared 728.35% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$57.5 million in 2022, then jumped by 220.25% to $69.1 million in 2023, then jumped by 42.73% to $98.6 million in 2024, then slumped by 179.54% to -$78.5 million in 2025, then surged by 138.2% to $30.0 million in 2026.
• The last three Net Cash Flow figures came in at $30.0 million (Q1 2026), -$78.5 million (Q4 2025), and $138.9 million (Q3 2025), per Business Quant data.